Wakamoto Pharmaceutical Co.,Ltd.
4512.T
Get informed when a big investor buys or sells
+ FollowMarket Cap$10.45B
Close$
Share Statistics
| Market cap | $10.45 Billion |
|---|---|
| Enterprise Value | $8.93 Billion |
| Dividend Yield | $3.50 (1.16%) |
| Earnings per Share | $6.55 |
| Beta | 0.47 |
| Outstanding Shares | 34,705,857 |
Return
| Return on Equity | 2.92% |
|---|---|
| Return on Assets | 2.16% |
| Return on Invested Capital | 1.79% |
Valuation & Multiples
| P/E Ratio | 30.53 |
|---|---|
| PEG | -28.75 |
| Price to Sales | 1.03 |
| Price to Book Ratio | 0.89 |
| Enterprise Value to Revenue | 0.88 |
| Enterprise Value to EBIT | 37.34 |
| Enterprise Value to Net Income | 26 |
| Total Debt to Enterprise | 0.04 |
| Debt to Equity | 0.03 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 5, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
November 6, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Wakamoto Pharmaceutical Co.,Ltd.
303 employees
CEO: Tomoyuki Hirai Headquartered in Tokyo, Japan, Wakamoto Pharmaceutical Co., Ltd. specializes in the production and distribution of both prescription and over-the-counter pharmaceuticals across the country. Their diverse offerings include Strong Wakamoto...